Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1.
Ropars J +18 more
europepmc +1 more source
Disease characteristics and treatment status of genetically confirmed spinal muscular atrophy patients: a cross-sectional survey in China. [PDF]
Zhang D +5 more
europepmc +1 more source
The 2025 Oligo Meeting in Budapest: Highlights of the 21<sup>st</sup> annual meeting of the oligonucleotide therapeutics society. [PDF]
Godinho BMDC, Guo S.
europepmc +1 more source
Newborn Screening for Spinal Muscular Atrophy in the UK: Use of Modelling to Identify Priorities for Ongoing Evaluation. [PDF]
Thokala P +6 more
europepmc +1 more source
Application of Biomarkers in Spinal Muscular Atrophy. [PDF]
Gao C, Zhan Y, Chen H, Deng C.
europepmc +1 more source
Reduction in Perioperative Risk in Patients with Spinal Muscular Atrophy Following the Release of Disease-Modifying Therapies: An Analysis of the National Surgical Quality Improvement Program Database. [PDF]
Toaz E, Pinto N, Kilner K, Cheon E.
europepmc +1 more source
Assessment of Fine Motor Abilities Among Children with Spinal Muscular Atrophy Treated with Nusinersen Using a New Touchscreen Application: A Pilot Study. [PDF]
Klemm I +7 more
europepmc +1 more source
Neurofilaments as Biomarkers of the Efficacy of Risdiplam Treatment in Early SMA Phenotypes Diagnosed by Newborn Screening. [PDF]
Pitarch-Castellano I +5 more
europepmc +1 more source
Effectiveness of Risdiplam Treatment in Adult Patients With Spinal Muscular Atrophy Type IIb-III. [PDF]
García Estévez DA.
europepmc +1 more source

